Guardant Health Inc

For the period ended Dec 31, 2023. Filed Feb 22, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 22, 2024

GH$155.35-2.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders' Equity

(in thousands, except share data)

Redeemable Noncontrolling Interest · Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Gain (Loss) · Accumulated Deficit · Total Stockholders’ Equity
Shares · Amount
Balance as of January 1, 2021	$57,100	100,213,985	$1	$1,902,389	$2,697	$(606,592)	$1,298,495
Cumulative effect adjustment for ASU 2020-06 adoption	—	—	—	(330,403)	—	4,437	(325,966)
Issuance of common stock upon exercise of stock options	—	693,074	—	8,112	—	—	8,112
Vesting of restricted stock units	—	750,160	—	—	—	—	—
Vesting of common stock exercised early	—	—	—	52	—	—	52
Issuance of common stock under employee stock purchase plan	—	110,227	—	9,753	—	—	9,753
Taxes paid related to net share settlement of restricted stock units	—	—	—	(83,759)	—	—	(83,759)
Stock-based compensation	—	—	—	151,449	—	—	151,449
Adjustment of redeemable noncontrolling interest	20,900	—	—	—	—	(20,900)	(20,900)
Reclassification of redeemable noncontrolling interest to noncontrolling interest liability	(78,000)	—	—	—	—	—	—
Other comprehensive loss, net of tax impact	—	—	—	—	(7,461)	—	(7,461)
Net loss	—	—	—	—	—	(384,770)	(384,770)
Balance as of December 31, 2021	—	101,767,446	1	1,657,593	(4,764)	(1,007,825)	645,005
Issuance of common stock upon exercise of stock options	—	228,311	—	2,625	—	—	2,625
Vesting of restricted stock units	—	315,673	—	—	—	—	—
Vesting of common stock exercised early	—	—	—	8	—	—	8
Issuance of common stock under employee stock purchase plan	—	307,953	—	9,316	—	—	9,316
Taxes paid related to net share settlement of restricted stock units	—	—	—	(7,878)	—	—	(7,878)
Stock-based compensation	—	—	—	94,685	—	—	94,685
Tender offer issued in connection with the Joint Venture Acquisition and acquisition related costs	—	—	—	(14,235)	—	—	(14,235)
Other comprehensive loss	—	—	—	—	(14,758)	—	(14,758)
Net loss	—	—	—	—	—	(654,588)	(654,588)
Balance as of December 31, 2022	—	102,619,383	1	1,742,114	(19,522)	(1,662,413)	60,180
Issuance of common stock upon follow-on public offering, net of offering costs of $21,131	—	14,375,000	—	381,369	—	—	381,369
Issuance of common stock upon registered direct offering	—	3,387,446	—	90,616	—	—	90,616
Issuance of common stock upon exercise of stock options	—	51,124	—	405	—	—	405
Vesting of restricted stock units	—	732,038	—	—	—	—	—
Issuance of common stock under employee stock purchase plan	—	464,870	—	10,154	—	—	10,154
Taxes paid related to net share settlement of restricted stock units	—	—	—	(11,197)	—	—	(11,197)
Stock-based compensation	—	—	—	90,759	—	—	90,759
Other comprehensive income	—	—	—	—	15,847	—	15,847
Net loss	—	—	—	—	—	(479,449)	(479,449)
Balance as of December 31, 2023	$—	121,629,861	$1	$2,304,220	$(3,675)	$(2,141,862)	$158,684

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.